公开(公告)号：US20180297997A1

公开(公告)日：2018-10-18

申请号：US16009596

申请日：2018-06-15

Applicant: Genentech, Inc.

Inventor： Yun-Xing Cheng ,  Rongbao Hua ,  Terry Kellar ,  Wei Li ,  Paul Gibbons ,  Mark Edward Zak

IPC: C07D471/04 ,  C07D519/00 ,  A61P11/06

CPC classification number: C07D471/04 ,  A61P11/06 ,  C07D519/00

Abstract: Compounds of Formula (I) and methods of use as Janus kinase inhibitors are described herein.

公开(公告)号：US20170369510A1

公开(公告)日：2017-12-28

申请号：US15699095

申请日：2017-09-08

Applicant: Genentech, Inc.

Inventor： Anthony Estrada ,  Snahel Patel ,  Terry Kellar ,  Malcolm Huestis ,  Daniel Shore ,  Michael Siu

IPC: C07D498/14 ,  A61K45/06 ,  A61K31/553 ,  C07D519/00 ,  A61K31/5383

CPC classification number: C07D498/14 ,  A61K31/5383 ,  A61K31/553 ,  A61K45/06 ,  C07D491/14 ,  C07D519/00

Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.

公开(公告)号：US11795170B2

公开(公告)日：2023-10-24

申请号：US17027352

申请日：2020-09-21

Applicant: Genentech, Inc.

Inventor： Mark Zak ,  Terry Kellar ,  Paul Gibbons

IPC: C07D487/04 ,  A61P11/06

CPC classification number: C07D487/04 ,  A61P11/06

Abstract: Compounds of Formula (I):




salts thereof and methods of making and use as Janus kinase inhibitors are described herein.

公开(公告)号：US20200165260A1

公开(公告)日：2020-05-28

申请号：US16777049

申请日：2020-01-30

Applicant: Genentech, Inc.

Inventor： Yun-Xing Cheng ,  Paul Gibbons ,  Terry Kellar ,  Wei Li ,  Rohan Mendonca ,  Po-wai Yuen ,  Mark Edward Zak ,  Lei Zhang

IPC: C07D487/04 ,  C07D519/00

Abstract: Compounds of Formula (00A) and salts thereof, wherein R1, R2 R3, R4 and n are defined herein, are useful as inhibitors of one or more Janus kinases. Also provided are pharmaceutical compositions that include a compound of Formula (00A) and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

公开(公告)号：US20180305355A1

公开(公告)日：2018-10-25

申请号：US15820515

申请日：2017-11-22

Applicant: Genentech, Inc.

Inventor： Mark Edward Zak ,  Nicholas Charles Ray ,  Simon Charles Goodacre ,  Rohan Mendonca ,  Terry Kellar ,  Yun-Xing Cheng ,  Wei Li ,  Po-wai Yuen

IPC: C07D471/04 ,  C07D487/04 ,  A61K31/519 ,  C07D519/00

CPC classification number: C07D471/04 ,  A61K31/519 ,  C07D487/04 ,  C07D519/00

Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.

公开(公告)号：US09346815B2

公开(公告)日：2016-05-24

申请号：US14720323

申请日：2015-05-22

Applicant: Genentech, Inc.

Inventor： Mark Edward Zak ,  Nicholas Charles Ray ,  Simon Charles Goodacre ,  Rohan Mendonca ,  Terry Kellar ,  Yun-Xing Cheng ,  Wei Li ,  Po-Wai Yuen

IPC: C07D487/04 ,  A61K31/519 ,  A61P11/06 ,  C07D519/00

CPC classification number: C07D471/04 ,  A61K31/519 ,  C07D487/04 ,  C07D519/00

Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.

Abstract translation: 本文描述了式（00A）的化合物和用作Janus激酶抑制剂的方法。

公开(公告)号：US20210009599A1

公开(公告)日：2021-01-14

申请号：US17027352

申请日：2020-09-21

Applicant: Genentech, Inc.

Inventor： Mark Zak ,  Terry Kellar ,  Paul Gibbons

IPC: C07D487/04 ,  A61P11/06

Abstract: Compounds of Formula (I): salts thereof and methods of making and use as Janus kinase inhibitors are described herein.

公开(公告)号：US10010549B2

公开(公告)日：2018-07-03

申请号：US14927267

申请日：2015-10-29

Applicant: Genentech, Inc.

Inventor： Anthony Estrada ,  Liting Dong ,  Kevin X. Chen ,  Paul Gibbons ,  Malcolm Huestis ,  Terry Kellar ,  Wen Liu ,  Changyou Ma ,  Joseph Lyssikatos ,  Alan Olivero ,  Snahel Patel ,  Daniel Shore ,  Michael Siu

IPC: A61K31/506 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/55 ,  A61K35/30 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D471/18 ,  C07D487/08 ,  C07D491/08 ,  C07D495/08 ,  C07D519/00 ,  C07D471/08 ,  A61K45/06 ,  A61K31/5386 ,  A61K31/553 ,  C07D417/14 ,  C07D487/14 ,  C07D487/18 ,  A61K31/444

CPC classification number: A61K31/506 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/55 ,  A61K31/553 ,  A61K35/30 ,  A61K45/06 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/08 ,  C07D471/18 ,  C07D487/08 ,  C07D487/14 ,  C07D487/18 ,  C07D491/08 ,  C07D495/08 ,  C07D519/00 ,  A61K2300/00

Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.

公开(公告)号：US20150336962A1

公开(公告)日：2015-11-26

申请号：US14720323

申请日：2015-05-22

Applicant: Genentech, Inc.

Inventor： Mark Edward Zak ,  Nicholas Charles Ray ,  Simon Charles Goodacre ,  Rohan Mendonca ,  Terry Kellar ,  Yun-Xing Cheng ,  Wei Li ,  Po-Wai Yuen

IPC: C07D487/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  A61K31/519 ,  C07D487/04 ,  C07D519/00

Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.

Abstract translation: 本文描述了式（00A）的化合物和用作Janus激酶抑制剂的方法。

公开(公告)号：US20220204517A1

公开(公告)日：2022-06-30

申请号：US17654131

申请日：2022-03-09

Applicant: Genentech, Inc.

Inventor： Yun-Xing Cheng ,  Paul Gibbons ,  Terry Kellar ,  Wei Li ,  Rohan Mendonca ,  Po-wai Yuen ,  Mark Edward Zak ,  Lei Zhang

IPC: C07D487/04 ,  C07D519/00

Abstract: Compounds of Formula (00A) and salts thereof, wherein R1, R2 R3, R4 and n are defined herein, are useful as inhibitors of one or more Janus kinases. Also provided are pharmaceutical compositions that include a compound of Formula (00A) and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.